AMLX
Amylyx Pharmaceuticals, Inc.
Key Financials
Net Income
$-144735000
↑ 52.0%
EPS (Diluted)
$-1.53
↑ 65.5%
Operating Income
$-153291000
↑ 51.3%
Revenue
$0
↓ 100.0%
Total Liabilities
$27.4M
↓ 5.1%
Total Assets
$332.6M
↑ 71.8%
Shareholders' Equity
$305.3M
↑ 85.3%
Cash & Equivalents
$226.7M
↑ 192.9%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 6/8/2026 | View on SEC |
| 4 | 6/8/2026 | View on SEC |
| 4 | 6/8/2026 | View on SEC |
| 4 | 6/8/2026 | View on SEC |
| 4 | 6/8/2026 | View on SEC |
| 8-K | 6/4/2026 | View on SEC |
| 4 | 5/26/2026 | View on SEC |
| SCHEDULE 13G/A | 5/15/2026 | View on SEC |
| 10-Q | 5/7/2026 | View on SEC |
| 8-K | 5/7/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | AMLX |
| Company Name | Amylyx Pharmaceuticals, Inc. |
| CIK | 1658551 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 617-682-0917 |